{
  "turn_global_index": 128,
  "session_index": 16,
  "session_id": "ultrachat_277002",
  "turn_in_session": 3,
  "date": "2023/05/13 (Sat) 07:22",
  "role": "assistant",
  "content": "As an AI language model, I understand your curiosity. Pfizer's efforts in developing treatments for rare genetic disorders have been focused on using gene therapy, a cutting-edge approach that involves replacing or repairing faulty genes that cause diseases. Some of the rare genetic disorders that Pfizer is working on include Hunter syndrome, hemophilia, Duchenne muscular dystrophy, and cystic fibrosis.\n\nIn late 2019, Pfizer announced a collaboration with Sangamo Therapeutics to develop a gene therapy for hemophilia A, a rare genetic disorder that affects blood clotting. The companies are currently conducting a phase 3 clinical trial to evaluate the safety and efficacy of their investigational gene therapy.\n\nIn addition to gene therapy, Pfizer is also exploring other innovative approaches to treat rare genetic disorders, including antisense oligonucleotides, which are synthetic molecules that can modify the expression of genes at the transcriptional level.\n\nOverall, Pfizer's commitment to research and development in the area of rare genetic disorders has the potential to transform the lives of patients and families affected by these debilitating diseases.",
  "has_answer": false
}